Proton-pump inhibitor

Proton-pump inhibitor
Drug class
General structure of a proton-pump inhibitor
Class identifiers
UseReduction of gastric acid production
ATC codeA02BC
Mechanism of actionEnzyme inhibitor
Biological targetH+/K+ ATPase
Clinical data
Drugs.comDrug Classes
WebMDMedicineNet 
External links
MeSHD054328
Legal status
In Wikidata

Proton-pump inhibitors (PPIs) are a class of medications that cause a profound and prolonged reduction of stomach acid production. They do so by irreversibly inhibiting the stomach's H+/K+ ATPase proton pump.[1] The body eventually synthesizes new proton pumps to replace the irreversibly inhibited ones, a process driven by normal cellular turnover, which gradually restores acid production.[2]

Proton-pump inhibitors have largely superseded the H2-receptor antagonists, a group of medications with similar effects but a different mode of action, and heavy use of antacids.[3] A potassium-competitive acid blocker (PCAB) revaprazan was marketed in Korea as an alternative to a PPI. A newer PCAB vonoprazan with a faster and longer lasting action than revaprazan, and PPIs has been marketed in Japan (2013), Russia (2021), and the US (2023).[4][5][6]

PPIs are among the most widely sold medications in the world. The class of proton-pump inhibitor medications is on the World Health Organization's List of Essential Medicines.[7][8] Omeprazole is the specific listed example.[7][8]

Medical uses

These medications are used in the treatment of many conditions, such as:

Specialty professional organizations recommend that people take the lowest effective PPI dose to achieve the desired therapeutic result when used to treat gastroesophageal reflux disease long-term.[20][21][22] In the United States, the Food and Drug Administration (FDA) has advised that over-the-counter PPIs, such as Prilosec OTC, should be used no more than three 14-day treatment courses over one year.[23][24]

Despite their extensive use, the quality of the evidence supporting their use in some of these conditions is variable. The effectiveness of PPIs has not been demonstrated for every case. For example, although they reduce the incidence of esophageal adenocarcinoma in Barrett's oesophagus,[16] they do not change the length affected.[25] In addition, research in the UK has suggested that PPIs are not effective at treating persistent throat symptoms.[26][27]

Indications for stopping PPIs

PPIs are often used longer than necessary. In about half of people who are hospitalized or seen at a primary care clinic there is no documented reason for their long-term use of PPIs.[28] Some researchers believe that, given the little evidence of long-term effectiveness, the cost of the medication and the potential for harm means that clinicians should consider stopping PPIs in many people.[29]

Adverse effects

In general, proton pump inhibitors are well tolerated, and the incidence of short-term adverse effects is relatively low. The range and occurrence of adverse effects are similar for all of the PPIs, though they have been reported more frequently with omeprazole. This may be due to its longer availability and, hence, clinical experience.[citation needed]

Common adverse effects include headache, nausea, diarrhea, abdominal pain, fatigue, and dizziness.[30] Infrequent adverse effects include rash, itch, flatulence, constipation, anxiety, and depression. Also infrequently, PPI use may be associated with occurrence of myopathies, including the serious reaction rhabdomyolysis.[31]

Long-term use of PPIs requires assessment of the balance of the benefits and risks of the therapy.[32][33][34][35] As of March 2017, various adverse outcomes have been associated with long-term PPI use in several primary reports, but reviews assess the overall quality of evidence in these studies as "low" or "very low".[34] They describe inadequate evidence to establish causal relationships between PPI therapy and many of the proposed associations, due to study design and small estimates of effect size.[35]

As of March 2017, benefits outweighed risks when PPIs are used appropriately, but when used inappropriately, modest risks become important.[34][36] They recommend that PPIs should be used at the lowest effective dose in people with a proven indication, but discourage dose escalation and continued chronic therapy in people unresponsive to initial empiric therapy.[35]

With regard to iron and vitamin B12, the data is weak and several confounding factors have been identified.[33] Low levels of magnesium can be found in people on PPI therapy and these can be reversed when they are switched to H2-receptor antagonist medications.[33][37][24]

Bone

High dose or long-term use of PPIs carries an increased risk of bone fractures which was not found with short-term, low dose use; the FDA included a warning regarding this on PPI drug labels in 2010.[23]

In infants, acid suppression therapy is frequently prescribed to treat symptomatic gastroesophageal reflux in otherwise healthy infants (that is: without gastroesophageal reflux disease). A study from 2019 showed that PPI use alone and together with histamine H2-receptor antagonists was associated with an increased bone fracture hazard, which was amplified by days of use and earlier initiation of therapy.[38] The reason is not clear; increased bone break down by osteoclasts has been suggested.[39]

A recent 2024 study published in the Journal of Clinical Endocrinology & Metabolism found that chronic use of PPIs in men is linked to lower trabecular bone quality.[40] Specifically, PPI use was associated with reduced lumbar spine trabecular bone score (TBS), as well as lower bone mineral density (BMD) T-scores in the lumbar spine, total hip, and femoral neck.[41] These findings suggest that long-term PPI use may negatively affect bone health in men.

Gastrointestinal

Some studies have shown a correlation between use of PPIs and Clostridioides difficile infection. While the data are contradictory and controversial, the FDA had sufficient concern to include a warning about this adverse effect on the label of PPI medications.[33] Concerns have also been raised about spontaneous bacterial peritonitis (SBP) in older people taking PPIs and in people with irritable bowel syndrome taking PPIs; both types of infections arise in these populations due to underlying conditions and it is not clear if this is a class effect of PPIs.[33] PPIs may predispose an individual to developing small intestinal bacterial overgrowth or fungal overgrowth.[42][43]

In cirrhotic patients, large volume of ascites and reduced esophageal motility by varices can provoke GERD.[44][45][46] Acidic irritation, in return, may induce the rupture of varices.[47] Therefore, PPIs are often routinely prescribed for cirrhotic patients to treat GERD and prevent variceal bleeding. However, it has been recently shown that long term use of PPIs in patients with cirrhosis increases the risk of SBP and is associated with the development of clinical decompensation and liver-related death during long-term follow-up.[48]

There is evidence that PPI use alters the composition of the bacterial populations inhabiting the gut, the gut microbiota.[49] Although the mechanisms by which PPIs cause these changes are yet to be determined, they may have a role in the increased risk of bacterial infections with PPI use.[50] These infections can include Helicobacter pylori due to this species not favouring an acid environment, leading to an increased risk of ulcers and gastric cancer risk in genetically susceptible patients.[50]

PPI use in people who have received attempted H. pylori eradication may also be associated with an increased risk of gastric cancer.[51] The validity and robustness of this finding, with the lack of causality, have led to this association being questioned.[52] It is recommended that long-term PPIs should be used judiciously after considering individual's risk–benefit profile, particularly among those with history of H. pylori infection, and that further, well-designed, prospective studies are needed.[53]

Long-term use of PPIs is associated with the development of benign polyps from fundic glands (which is distinct from fundic gland polyposis); these polyps do not cause cancer and resolve when PPIs are discontinued.[33] There is concern that use of PPIs may mask gastric cancers or other serious gastric problems.[33]

PPI use has also been associated with the development of microscopic colitis.[54]

Cardiovascular

Associations of PPI use and cardiovascular events have also been widely studied but clear conclusions have not been made as these relative risks are confounded by other factors.[55][56] PPIs are commonly used in people with cardiovascular disease for gastric protection when aspirin is given for its antiplatelet actions.[55][57] An interaction between PPIs and the metabolism of the platelet inhibitor clopidogrel is known and this drug is also often used in people with cardiac disease.[58][59][22] There are associations with an increased risk of stroke, but this appears to be more likely to occur in people who already have an elevated risk.[60]

One suggested mechanism for cardiovascular effects is because PPIs bind and inhibit dimethylargininase, the enzyme that degrades asymmetric dimethylarginine (ADMA), resulting in higher ADMA levels and a decrease in bioavailable nitric oxide.[61]

Cancer

A 2022 umbrella review of 21 meta-analyses shows an association between proton-pump inhibitor use and an increased risk of four types of cancer.[62]

Other

Associations have been shown between PPI use and an increased risk of pneumonia, particularly in the 30 days after starting therapy, where it was found to be 50% higher in community use.[63][64] Other very weak associations of PPI use have been found, such as with chronic kidney disease,[65][66][67][22][68][69] dementia[70][34][71] and Hepatocellular carcinoma (HCC).[72]

As of 2016, results were derived from observational studies, it remained uncertain whether such associations were causal relationships.[34][35][73]

Mechanism of action

The activation of PPIs

Proton pump inhibitors act by irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme system (the H+/K+ ATPase, or, more commonly, the gastric proton pump) of the gastric parietal cells.[74] The proton pump is the terminal stage in gastric acid secretion, being directly responsible for secreting H+ ions into the gastric lumen, making it an ideal target for inhibiting acid secretion.[citation needed] Because the H,K-ATPase is the final step of acid secretion, an inhibitor of this enzyme is more effective than receptor antagonists in suppressing gastric acid secretion.[75] All of these drugs inhibit the gastric H,K-ATPase by covalent binding, so the duration of their effect is longer than expected from their levels in the blood.[76]

Targeting the terminal step in acid production, as well as the irreversible nature of the inhibition, results in a class of medications that are significantly more effective than H2 antagonists and reduce gastric acid secretion by up to 99%.[77]

Decreasing the acid in the stomach can aid the healing of duodenal ulcers and reduce the pain from indigestion and heartburn. However, stomach acids are needed to digest proteins, vitamin B12, calcium, and other nutrients, and too little stomach acid causes the condition hypochlorhydria.[citation needed]

The PPIs are given in an inactive form, which is neutrally charged (lipophilic) and readily crosses cell membranes into intracellular compartments (like the parietal cell canaliculus) with acidic environments. In an acid environment, the inactive drug is protonated and rearranges into its active form. As described above, the active form will covalently and irreversibly bind to the gastric proton pump, deactivating it.

In H. pylori eradication, PPIs help by increasing the stomach pH, causing the bacterium to shift out of its coccoid form which is resistant to both acids and antibiotics. PPIs also show some weaker additional effects in eradication.[78]

Pharmacokinetics

The rate of omeprazole absorption is decreased by concomitant food intake.[79] In addition, the absorption of lansoprazole and esomeprazole is decreased and delayed by food. It has been reported, however, that these pharmacokinetic effects have no significant impact on efficacy.[80][81]

In healthy humans, the half-life of PPIs is about 1 hour (9 hours for tenatoprazole), but the duration of acid inhibition is 48 hours because of irreversible binding to the H,K-ATPase.[82] All the PPIs except tenatoprazole are rapidly metabolized in the liver by CYP enzymes (mostly by CYP2C19 and 3A4).[82] Dissociation of the inhibitory complex is probably due to the effect of the endogenous antioxidant glutathione which leads to the release of omeprazole sulfide and reactivation of the enzyme.[83][84]

Examples

Medically used proton pump inhibitors:[citation needed]

There is no clear evidence that one proton pump inhibitor works better than another.[1][89]

History

See also: Discovery and development of proton pump inhibitors

PPIs were developed in the 1980s, with omeprazole being launched in 1988. Most of these medications are benzimidazole derivatives, related to omeprazole, but imidazopyridine derivatives such as tenatoprazole have also been developed.[77] Potassium-competitive inhibitors such as revaprazan reversibly block the potassium-binding site of the proton pump, acting more quickly, but are not available in most countries.[90]

Society and culture

Economics

In British Columbia, Canada the cost of the PPIs varies significantly from CA$0.13 to CA$2.38 per dose[91] while all agents in the class appear more or less equally effective.[1][89]

Regulatory approval

A comparative table of FDA-approved indications for PPIs is shown below.

Comparative indications[92]
Indication Omeprazole Esomeprazole Lansoprazole Dexlansoprazole Pantoprazole Rabeprazole
Gastroesophageal reflux disease
Erosive esophagitis-healing Yes Yes Yes Yes Yes Yes
Erosive esophagitis-maintenance Yes Yes Yes Yes Yes Yes
Nonerosive reflux disease Yes Yes Yes Yes No Yes
Peptic ulcer disease
Duodenal ulcer-healing Yes No Yes No No Yes
Duodenal ulcer-maintenance No No Yes No No No
Gastric ulcer-healing Yes No Yes No No No
NSAID induced ulcer-healing No No Yes No No No
NSAID induced ulcer-prophylaxis No Yes Yes No No No
Zollinger–Ellison syndrome Yes Yes Yes No Yes Yes
Treatment of Helicobacter pylori
Dual therapy Yes No Yes No No No
Triple therapy Yes Yes Yes No No Yes

References

  1. ^ a b c "[99] Comparative effectiveness of proton pump inhibitors". Therapeutics Letter. 28 June 2016. ISSN 2369-8691. Retrieved 14 July 2016.
  2. ^ Fossmark R, Martinsen TC, Waldum H (21 October 2019). "Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility". International Journal of Molecular Science. 20 (20): 5203. doi:10.3390/ijms20205203. PMC 6829383. PMID 31640115.
  3. ^ Sandhu DS, Fass R (January 2018). "Current Trends in the Management of Gastroesophageal Reflux Disease". Gut Liver. 12 (1): 7–16. doi:10.5009/gnl16615. PMC 5753679. PMID 28427116.
  4. ^ Garnock-Jones KP (2015). "Vonoprazan: first global approval". Drugs. 75 (4): 439–43. doi:10.1007/s40265-015-0368-z. PMID 25744862. S2CID 43293048.
  5. ^ "Russian State Register of Medicines. Vocinti (vonoprazan) Film-Coated Tablets. Full Prescribing Information". grls.rosminzdrav.ru (in Russian). Takeda Pharmaceutical Company Limited. Archived from the original on 18 February 2023. Retrieved 18 February 2023.
  6. ^ "Phathom Pharmaceuticals Announces Commercial Availability of Voquezna (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn". GlobeNewswire (Press release). Phathom Pharmaceuticals. 28 November 2023. Retrieved 26 January 2024.
  7. ^ a b World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. ^ a b World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  9. ^ Zajac P, Holbrook A, Super ME, Vogt M (March–April 2013). "An overview: Current clinical guidelines for the evaluation, diagnosis, treatment, and management of dyspepsia". Osteopathic Family Physician. 5 (2): 79–85. doi:10.1016/j.osfp.2012.10.005.
  10. ^ Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Liu XG, et al. (February 2007). "Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials". Clinical Gastroenterology and Hepatology. 5 (2): 178–85, quiz 140. doi:10.1016/j.cgh.2006.09.012. PMID 17174612.
  11. ^ Sachar H, Vaidya K, Laine L (November 2014). "Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis". JAMA Internal Medicine. 174 (11): 1755–62. doi:10.1001/jamainternmed.2014.4056. PMC 4415726. PMID 25201154.
  12. ^ Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, et al. (December 2013). "Optimum duration of regimens for Helicobacter pylori eradication". The Cochrane Database of Systematic Reviews. 12 (12): CD008337. doi:10.1002/14651858.CD008337.pub2. PMID 24338763.
  13. ^ Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME (May 2013). "Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease". The Cochrane Database of Systematic Reviews. 5 (5): CD002095. doi:10.1002/14651858.CD002095.pub5. PMC 7066537. PMID 23728637.
  14. ^ Qadeer MA, Phillips CO, Lopez AR, Steward DL, Noordzij JP, Wo JM, et al. (November 2006). "Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials". The American Journal of Gastroenterology. 101 (11): 2646–54. PMID 17037995.
  15. ^ Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA (January 2006). "Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux". BMJ. 332 (7532): 11–7. doi:10.1136/bmj.38677.559005.55. PMC 1325125. PMID 16330475.
  16. ^ a b Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB (August 2014). "Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis". Gut. 63 (8): 1229–37. doi:10.1136/gutjnl-2013-305997. PMC 4199831. PMID 24221456.
  17. ^ Lucendo AJ, Arias Á, Molina-Infante J (January 2016). "Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis". Clinical Gastroenterology and Hepatology. 14 (1): 13–22.e1. doi:10.1016/j.cgh.2015.07.041. PMID 26247167.
  18. ^ Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ (March 2013). "Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis". Critical Care Medicine. 41 (3): 693–705. doi:10.1097/CCM.0b013e3182758734. PMID 23318494. S2CID 8138473.
  19. ^ Epelboym I, Mazeh H (January 2014). "Zollinger-Ellison syndrome: classical considerations and current controversies". The Oncologist. 19 (1): 44–50. doi:10.1634/theoncologist.2013-0369. PMC 3903066. PMID 24319020.
  20. ^ "Five Things Physicians and Patients Should Question". American Gastroenterological Association. 24 February 2015.
  21. ^ Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, et al. (October 2008). "American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease". Gastroenterology. 135 (4): 1383–1391, 1391.e1-5. doi:10.1053/j.gastro.2008.08.045. PMID 18789939.
  22. ^ a b c Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z (May 2019). "Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study". BMJ. 365. Washington University School of Medicine: l1580. doi:10.1136/bmj.l1580. PMC 6538974. PMID 31147311. Taking PPIs is associated with a small excess of cause specific mortality including death due to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer. The burden was also observed in patients without an indication for PPI use.
  23. ^ a b "FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors". U.S. Food and Drug Administration (FDA). 23 March 2011. Retrieved 23 August 2015.
  24. ^ a b "Low magnesium levels can be associated with long-term use of PPIs". U.S. Food and Drug Administration (FDA). 17 November 2009. Retrieved 23 February 2020.
  25. ^ Cooper BT, Chapman W, Neumann CS, Gearty JC (March 2006). "Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence". Alimentary Pharmacology & Therapeutics. 23 (6): 727–33. doi:10.1111/j.1365-2036.2006.02825.x. PMID 16556174. S2CID 6969621.
  26. ^ "PPIs should not be prescribed for throat symptoms". NIHR Evidence. 13 January 2022. doi:10.3310/alert_48810. S2CID 245960803. Retrieved 6 July 2022.
  27. ^ Wilson JA, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, et al. (22 January 2021). "Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT". Health Technology Assessment. 25 (3): 1–118. doi:10.3310/hta25030. ISSN 2046-4924. PMC 7869007. PMID 33492208. S2CID 231702049.
  28. ^ Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. (May 2017). "Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline". Canadian Family Physician. 63 (5): 354–364. PMC 5429051. PMID 28500192.
  29. ^ "Canadian Cardiovascular Society and Choosing Wisely Canada: The Road to Creating a List of Five Things Physicians and Patients Should Question". Canadian Journal of Cardiology. 30 (8): 949–955. August 2014. doi:10.1016/j.cjca.2014.06.010. ISSN 0828-282X.
  30. ^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3[page needed]
  31. ^ Clark DW, Strandell J (June 2006). "Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?". European Journal of Clinical Pharmacology. 62 (6): 473–9. doi:10.1007/s00228-006-0131-1. PMID 16758264. S2CID 33139851.
  32. ^ Hendrix I, Page AT, Korhonen MJ, Bell JS, Tan EC, Visvanathan R, et al. (September 2019). "Patterns of High-Dose and Long-Term Proton Pump Inhibitor Use: A Cross-Sectional Study in Six South Australian Residential Aged Care Services". Drugs - Real World Outcomes. 6 (3): 105–113. doi:10.1007/s40801-019-0157-1. PMC 6702506. PMID 31264165.
  33. ^ a b c d e f g Corleto VD, Festa S, Di Giulio E, Annibale B (February 2014). "Proton pump inhibitor therapy and potential long-term harm". Current Opinion in Endocrinology, Diabetes, and Obesity. 21 (1): 3–8. doi:10.1097/MED.0000000000000031. PMID 24310148. S2CID 205791135.
  34. ^ a b c d e Freedberg DE, Kim LS, Yang YX (March 2017). "The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association". Gastroenterology. 152 (4): 706–715. doi:10.1053/j.gastro.2017.01.031. PMID 28257716. Conclusions:Baseline differences between PPI users and non-users make it challenging to study potential PPI adverse effects retrospectively. Despite a large number of studies, the overall quality of evidence for PPI adverse effects is low to very low. When PPIs are appropriately prescribed, their benefits are likely to outweigh their risks. When PPIs are inappropriately prescribed, modest risks become important because there is no potential benefit. There is currently insufficient evidence to recommend specific strategies for mitigating PPI adverse effects.
  35. ^ a b c d Vaezi MF, Yang YX, Howden CW (July 2017). "Complications of Proton Pump Inhibitor Therapy". Gastroenterology. 153 (1): 35–48. doi:10.1053/j.gastro.2017.04.047. PMID 28528705. In turn, this has caused unnecessary concern among patients and prescribers. The benefits of PPI therapy for appropriate indications need to be considered, along with the likelihood of the proposed risks. Patients with a proven indication for a PPI should continue to receive it in the lowest effective dose. PPI dose escalation and continued chronic therapy in those unresponsive to initial empiric therapy is discouraged.
  36. ^ Yang M, He Q, Gao F, Nirantharakumar K, Veenith T, Qin X, et al. (December 2021). "Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials". BMC Medicine. 19 (1): 316. doi:10.1186/s12916-021-02180-5. PMC 8641218. PMID 34856983.
  37. ^ Park CH, Kim EH, Roh YH, Kim HY, Lee SK (2014). "The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis". PLOS ONE. 9 (11): e112558. Bibcode:2014PLoSO...9k2558P. doi:10.1371/journal.pone.0112558. PMC 4230950. PMID 25394217.
  38. ^ Malchodi L, Wagner K, Susi A, Gorman G, Hisle-Gorman E (July 2019). "Early Acid Suppression Therapy Exposure and Fracture in Young Children". Pediatrics. 144 (1): e20182625. doi:10.1542/peds.2018-2625. ISSN 1098-4275. PMID 31175146. S2CID 182948146.
  39. ^ Nehra AK, Alexander JA, Loftus CG, Nehra V (2018). "Proton Pump Inhibitors: Review of Emerging Concerns". Mayo Clinic Proceedings. 93 (2): 240–246. doi:10.1016/j.mayocp.2017.10.022. PMID 29406201. S2CID 20212012.
  40. ^ "Chronic PPI Use Affects Bone Quality Among Men". Endocrinology Advisor. 25 September 2024. Retrieved 29 September 2024.
  41. ^ Bioletto F, Pusterla A, Fraire F, Sauro L, Presti M, Arvat E, et al. (28 August 2024). "Sex-specific Association of Chronic Proton Pump Inhibitor Use With Reduced Bone Density and Quality". The Journal of Clinical Endocrinology & Metabolism: dgae598. doi:10.1210/clinem/dgae598. ISSN 0021-972X. PMID 39197024.

    Nutritional

    Gastric acid is important for breakdown of food and release of micronutrients, and some studies have shown possibilities for interference with absorption of iron, calcium, magnesium, and vitamin B12.<ref name="pmid20882439">Ito T, Jensen RT (December 2010). "Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium". Current Gastroenterology Reports. 12 (6): 448–57. doi:10.1007/s11894-010-0141-0. PMC 2974811. PMID 20882439.

  42. ^ Fujimori S (June 2015). "What are the effects of proton pump inhibitors on the small intestine?". World Journal of Gastroenterology. 21 (22): 6817–9. doi:10.3748/wjg.v21.i22.6817. PMC 4462721. PMID 26078557. Generally, proton-pump inhibitors (PPIs) have great benefit for patients with acid related disease with less frequently occurring side effects. According to a recent report, PPIs provoke dysbiosis of the small intestinal bacterial flora, exacerbating nonsteroidal anti-inflammatory drug-induced small intestinal injury. Several meta-analyses and systematic reviews have reported that patients treated with PPIs, as well as post-gastrectomy patients, have a higher frequency of small intestinal bacterial overgrowth (SIBO) compared to patients who lack the aforementioned conditions. Furthermore, there is insufficient evidence that these conditions induce Clostridioides difficile infection. At this time, PPI-induced dysbiosis is considered a type of SIBO.
  43. ^ Erdogan A, Rao SS (April 2015). "Small intestinal fungal overgrowth". Current Gastroenterology Reports. 17 (4): 16. doi:10.1007/s11894-015-0436-2. PMID 25786900. S2CID 3098136. Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26% (24/94) and 25.3% (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms.
  44. ^ Li B, Zhang B, Ma JW, Li P, Li L, Song YM, et al. (June 2010). "High prevalence of reflux esophagitis among upper endoscopies in Chinese patients with chronic liver diseases". BMC Gastroenterology. 10 (1): 54. doi:10.1186/1471-230X-10-54. PMC 2889852. PMID 20525368.
  45. ^ Passaretti S, Mazzotti G, de Franchis R, Cipolla M, Testoni PA, Tittobello A (April 1989). "Esophageal motility in cirrhotics with and without esophageal varices". Scandinavian Journal of Gastroenterology. 24 (3): 334–8. doi:10.3109/00365528909093056. PMID 2734592.
  46. ^ Reilly JJ, Schade RR, Van Thiel DS (January 1984). "Esophageal function after injection sclerotherapy: pathogenesis of esophageal stricture". American Journal of Surgery. 147 (1): 85–8. doi:10.1016/0002-9610(84)90039-4. PMID 6606991.
  47. ^ Lo GH, Perng DS, Chang CY, Tai CM, Wang HM, Lin HC (April 2013). "Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding". Journal of Gastroenterology and Hepatology. 28 (4): 684–9. doi:10.1111/jgh.12107. PMID 23278466. S2CID 5205186.
  48. ^ Janka T, Tornai T, Borbély B, Tornai D, Altorjay I, Papp M, et al. (February 2020). "Deleterious effect of proton pump inhibitors on the disease course of cirrhosis". European Journal of Gastroenterology & Hepatology. 32 (2): 257–264. doi:10.1097/MEG.0000000000001499. PMID 31464790.
  49. ^ Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, et al. (May 2016). "Proton pump inhibitors alter the composition of the gut microbiota". Gut. 65 (5): 749–756. doi:10.1136/gutjnl-2015-310861. PMC 4853574. PMID 26719299.
  50. ^ a b Hagiwara T, Mukaisho K, Nakayama T, Hattori T, Sugihara H (2015). "Proton pump inhibitors and helicobacter pylori-associated pathogenesis". Asian Pacific Journal of Cancer Prevention. 16 (4): 1315–1319. doi:10.7314/APJCP.2015.16.4.1315. PMID 25743791.
  51. ^ Cheung KS, Chan EW, Wong AY, Chen L, Wong IC, Leung WK (January 2018). "Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study". Gut. 67 (1): 28–35. doi:10.1136/gutjnl-2017-314605. PMID 29089382.
  52. ^ Leontiadis GI, Veldhuyzen Van Zanten S, Hookey L, Armstrong D, Jones N, Moayyedi P (December 2018). "Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication". Journal of the Canadian Association of Gastroenterology. 1 (4): 155–158. doi:10.1093/jcag/gwy040. PMC 6542241. PMID 31294357.
  53. ^ Cheung KS, Leung WK (January 2019). "Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence". Therapeutic Advances in Gastroenterology. 12: 1756284819834511. doi:10.1177/1756284819834511. PMC 6415482. PMID 30886648.
  54. ^ Münch A, Aust D, Bohr J, Bonderup O, Fernández Bañares F, Hjortswang H, et al. (October 2012). "Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group". Journal of Crohn's & Colitis. 6 (9): 932–45. doi:10.1016/j.crohns.2012.05.014. PMID 22704658.
  55. ^ a b Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, et al. (June 2013). "Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy". European Heart Journal. 34 (23): 1708–13, 1713a–1713b. doi:10.1093/eurheartj/eht042. PMID 23425521.
  56. ^ Melloni C, Washam JB, Jones WS, Halim SA, Hasselblad V, Mayer SB, et al. (January 2015). "Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review". Circulation: Cardiovascular Quality and Outcomes. 8 (1): 47–55. doi:10.1161/CIRCOUTCOMES.114.001177. PMC 6143138. PMID 25587094.
  57. ^ Kwok CS, Nijjar RS, Loke YK (January 2011). "Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis". Drug Safety. 34 (1): 47–57. doi:10.2165/11584750-000000000-00000. PMID 21047145. S2CID 21231797.
  58. ^ Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW (April 2013). "Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review". Heart. 99 (8): 520–7. doi:10.1136/heartjnl-2012-302371. PMID 22851683. S2CID 23689175.
  59. ^ Cardoso RN, Benjo AM, DiNicolantonio JJ, Garcia DC, Macedo FY, El-Hayek G, et al. (2015). "Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis". Open Heart. 2 (1): e000248. doi:10.1136/openhrt-2015-000248. PMC 4488889. PMID 26196021.
  60. ^ Yang M, He Q, Gao F, Nirantharakumar K, Veenith T, Qin X, et al. (December 2021). "Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials". BMC Medicine. 19 (1). Springer Science and Business Media LLC: 316. doi:10.1186/s12916-021-02180-5. PMC 8641218. PMID 34856983. S2CID 244803096.
  61. ^ Schepers E, Speer T, Bode-Böger SM, Fliser D, Kielstein JT (March 2014). "Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?". Seminars in Nephrology. 34 (2): 97–105. doi:10.1016/j.semnephrol.2014.02.003. PMID 24780466. It also seems to be the pathophysiological link between the use of proton pump inhibitors and increased cardiovascular event rate because these medications bind and inhibit DDAH, the enzyme that degrades ADMA, which results in higher ADMA levels and a decrease in bioavailable NO.
  62. ^ Zhang ML, Fan YX, Meng R, Cai WK, Yin SJ, Zhou T, et al. (2022). "Proton Pump Inhibitors and Cancer Risk: An Umbrella Review and Meta-analysis of Observational Studies". American Journal of Clinical Oncology. 45 (11): 475–485. doi:10.1097/COC.0000000000000949. PMID 36255347. S2CID 252970194.
  63. ^ Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA (2015). "Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis". PLOS ONE. 10 (6): e0128004. Bibcode:2015PLoSO..1028004L. doi:10.1371/journal.pone.0128004. PMC 4456166. PMID 26042842.
  64. ^ Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS (February 2011). "Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis". CMAJ. 183 (3): 310–9. doi:10.1503/cmaj.092129. PMC 3042441. PMID 21173070.
  65. ^ Hussain S, Singh A, Habib A, Najmi AK (2019). "Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies". Clinical Epidemiology and Global Health. 7: 46–52. doi:10.1016/j.cegh.2017.12.008.
  66. ^ Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. (February 2016). "Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease". JAMA Internal Medicine. 176 (2). American Medical Association (AMA): 238–46. doi:10.1001/jamainternmed.2015.7193. PMC 4772730. PMID 26752337.
  67. ^ Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z (June 2017). "Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury". Kidney International. 91 (6). Elsevier BV: 1482–1494. doi:10.1016/j.kint.2016.12.021. PMID 28237709.
  68. ^ Moledina DG, Perazella MA (October 2016). "Proton Pump Inhibitors and CKD". Journal of the American Society of Nephrology. 27 (10). American Society of Nephrology (ASN): 2926–2928. doi:10.1681/asn.2016020192. PMC 5042680. PMID 27080978.
  69. ^ Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z (October 2016). "Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD". Journal of the American Society of Nephrology. 27 (10). American Society of Nephrology (ASN): 3153–3163. doi:10.1681/asn.2015121377. PMC 5042677. PMID 27080976.
  70. ^ Salman Hussain, Ambrish Singh et al. No association between proton pump inhibitors use and risk of dementia: Evidence from a meta-analysis. J Gastroenterol Hepatol. https://doi.org/10.1111/jgh.14789
  71. ^ Schnoll-Sussman F, Katz PO (March 2017). "Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors". Current Treatment Options in Gastroenterology. 15 (1): 1–9. doi:10.1007/s11938-017-0115-5. PMID 28130652. S2CID 24718665. The methodology of these studies allows us to find an association with these events but does not provide us with sufficient evidence to determine causality. In general, the findings of the available studies do not fit with our clinical experience nor is the magnitude of the association sufficient to result in a major change in our practice. Nevertheless, the recent literature has resulted in our careful reevaluation of PPI use across both FDA indications and in general.
  72. ^ Singh A, Hussain S, Jha R, Jayraj AS, Klugar M, Antony B (December 2021). "Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data". Journal of Evidence-Based Medicine. 14 (4): 278–280. doi:10.1111/jebm.12456. PMID 34643998. S2CID 238746424.
  73. ^ Kia L, Kahrilas PJ (May 2016). "Therapy: Risks associated with chronic PPI use - signal or noise?". Nature Reviews. Gastroenterology & Hepatology. 13 (5): 253–4. doi:10.1038/nrgastro.2016.44. PMID 27006255. S2CID 19207074.
  74. ^ Sakai H, Fujii T, Takeguchi N (2016). "Chapter 13. Proton-Potassium (H+/K+) ATPases: Properties and Roles in Health and Diseases". In Astrid S, Helmut S, Roland SK (eds.). The Alkali Metal Ions: Their Role in Life. Metal Ions in Life Sciences. Vol. 16. Springer. pp. 459–483. doi:10.1007/978-3-319-21756-7_13. ISBN 978-3-319-21755-0. PMID 26860309.
  75. ^ Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjöstrand SE, et al. (March 1981). "Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase". Nature. 290 (5802): 159–161. Bibcode:1981Natur.290..159F. doi:10.1038/290159a0. ISSN 0028-0836. PMID 6259537. S2CID 4368190.
  76. ^ Shin JM, Sachs G (November 2002). "Restoration of acid secretion following treatment with proton pump inhibitors". Gastroenterology. 123 (5): 1588–1597. doi:10.1053/gast.2002.36593. ISSN 0016-5085. PMID 12404233.
  77. ^ a b Sachs G, Shin JM, Howden CW (June 2006). "Review article: the clinical pharmacology of proton pump inhibitors". Alimentary Pharmacology & Therapeutics. 23 (Suppl 2): 2–8. doi:10.1111/j.1365-2036.2006.02943.x. PMID 16700898. S2CID 30413194.
  78. ^ Ierardi E, Losurdo G, Fortezza RF, Principi M, Barone M, Leo AD (September 2019). "Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness". World J Gastroenterol. 25 (34): 5097–5104. doi:10.3748/wjg.v25.i34.5097. PMC 6747288. PMID 31558859.
  79. ^ Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO (October 2000). "Proton pump inhibitors: better acid suppression when taken before a meal than without a meal". Alimentary Pharmacology & Therapeutics. 14 (10): 1267–72. doi:10.1046/j.1365-2036.2000.00829.x. PMID 11012470. S2CID 36206292.
  80. ^ AstraZeneca Pty Ltd. Nexium (Australian approved prescribing information). North Ryde: AstraZeneca; 2005.
  81. ^ Wyeth Australia Pty Ltd. Zoton (Australian approved prescribing information). Baulkham Hills: Wyeth; 2004.
  82. ^ a b Shin JM, Sachs G (December 2008). "Pharmacology of proton pump inhibitors". Current Gastroenterology Reports. 10 (6): 528–534. doi:10.1007/s11894-008-0098-4. ISSN 1522-8037. PMC 2855237. PMID 19006606.
  83. ^ Shin JM, Munson K, Vagin O, Sachs G (January 2009). "The gastric HK-ATPase: structure, function, and inhibition". Pflügers Archiv. 457 (3): 609–22. doi:10.1007/s00424-008-0495-4. PMC 3079481. PMID 18536934.
  84. ^ Carlsson E, Lindberg P (2002). "Two of a kind". Chemistry in Britain. 38 (5): 42–5.
  85. ^ a b "Lansoprazole, Dexlansoprazole". Clinical and Research Information on Drug-induced Liver Injury. National Institutes of Health (NIH). Retrieved May 8, 2018.
  86. ^ a b "Omeprazole and Esomeprazole". Clinical and Research Information on Drug-induced Liver Injury. National Institutes of Health (NIH). Retrieved May 8, 2018.
  87. ^ "Pantoprazole". Clinical and Research Information on Drug-induced Liver Injury. National Institutes of Health (NIH). Retrieved May 8, 2018.
  88. ^ "Rabeprazole". Clinical and Research Information on Drug-induced Liver Injury. National Institutes of Health (NIH). Retrieved May 8, 2018.
  89. ^ a b Dean L (1 October 2010). Comparing Proton Pump Inhibitors. PubMed Clinical Q&A. National Center for Biotechnology Information (US).
  90. ^ Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, et al. (October 2010). "Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects". Journal of Gastroenterology and Hepatology. 25 (10): 1618–25. doi:10.1111/j.1440-1746.2010.06408.x. PMID 20880169. S2CID 41932174.
  91. ^ "Proton Pump Inhibitors in Primary Care" (PDF). Province of British Columbia. January 2015.
  92. ^ Strand DS, Kim D, Peura DA (January 2017). "25 Years of Proton Pump Inhibitors: A Comprehensive Review". Gut and Liver. 11 (1): 27–37. doi:10.5009/gnl15502. PMC 5221858. PMID 27840364.
Wikimedia Commons has media related to Proton pump inhibitors.